Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 9Breast Neoplasms 8Triple Negative Breast Neoplasms 2Lung Neoplasms 2Carcinoma, Neuroendocrine 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neutropenia 1Neoplasm Metastasis 1Intracranial Germ Cell CNS Tumor, Childhood 1Fallopian Tube Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Small Cell 1Carcinoma, Pancreatic Ductal 1

Interventions

Cisplatin 7Etoposide 6pembrolizumab 4Topotecan 4Pemetrexed 4Carboplatin 4Gemcitabine 3belinostat 2Temozolomide 2RRx-001 2Paclitaxel 2vosaroxin 1vinflunine 1veliparib 1taxane 1sagopilone 1sacituzumab govitecan 1pomalidomide 1lurtotecan 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1bemiparin 1belotecan 1atezolizumab 1apalutamide 1alvocidib 1abiraterone 1Vinorelbine 1Tomography, X-Ray Computed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Small Cell × EC regimen × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡